RUTHERFORD, N.J., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today the presentation of results from two independent cervical cancer-related studies during the 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015) scheduled to take place on September 17-21, 2015 in Lisbon, Portugal.
The first study entitled "Chromosomal Gains Measured by Fluorescence in situ Hybridization in Cytology Samples" was conducted in collaboration with the National Cancer Institute (NCI). The study evaluated the gain of three individual genomic loci by Fluorescence in situ Hybridization (FISH) as a biomarker-guided tool for detecting cancerous and precancerous cells in 294 liquid-based cervical cytology samples from women undergoing routine cervical cancer screenings in the United States. This is the second study done in collaboration with the NCI that assesses the use of biomarkers included in CGI's FHACT® test.
The second study was conducted in collaboration with Kamineni Hospital, Hyderabad (India). The poster titled "Evaluation of Gain of Four Chromosomal Loci by Fluorescence in-situ Hybridization on Pap Smears of Women in India" provides insights about the correlation of CGI's FHACT® results and cervical cytology. The goal of the study was to evaluate the potential for detection using visual inspection with acetic acid (VIA), HR-HPV subtyping, and fluorescence in-situ hybridization (FISH) at the time of cytologic assessment for women with underlying high grade cervical disease.
The poster abstracts can be viewed online through the HPV 2015 website at: http://hpv2015.org/scientific-information/abstracts-pdf#.Vfolv7TxhUQ
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended June 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.